title: Thrombopoietin treatment of one graft in a double cord blood transplant provides early platelet recovery while contributing to long-term engraftment in NSG mice.
abstract: Human cord blood (CB) hematopoietic stem cell (HSC) transplants demonstrate delayed early neutrophil and platelet recovery and delayed longer term immune reconstitution compared to bone marrow and mobilized peripheral blood transplants. Despite advances in enhancing early neutrophil engraftment, platelet recovery after CB transplantation is not significantly altered when compared to contemporaneous controls. Recent studies have identified a platelet-biased murine HSC subset, maintained by thrombopoietin (TPO), which has enhanced capacity for short- and long-term platelet reconstitution, can self-renew, and can give rise to myeloid- and lymphoid-biased HSCs. In previous studies, we have shown that transplantation of human CB CD34(+) cells precultured in TPO as a single graft accelerates early platelet recovery as well as yielding long-term repopulation in immune-deficient mice. In this study, using a double CB murine transplant model, we investigated whether TPO cultured human CB CD34(+) cells have a competitive advantage or disadvantage over untreated human CB CD34(+) cells in terms of (1) short-term and longer term platelet recovery and (2) longer term hematological recovery. Our studies demonstrate that the TPO treated graft shows accelerated early platelet recovery without impairing the platelet engraftment of untreated CD34(+) cells. Notably, this was followed by a dominant contribution to platelet production through the untreated CD34(+) cell graft over the intermediate to longer term. Furthermore, although the contribution of the TPO treated graft to long-term hematological engraftment was reduced, the TPO treated and untreated grafts both contributed significantly to long-term chimerism in vivo.
authors.affiliation: 1 Jon J. van Rood Center for Clinical Transfusion Research , Sanquin Blood Supply Foundation, Leiden, The Netherlands .
authors.forename: Mark
authors.initials: M
authors.lastname: van der Garde
authors.forename: Yvette
authors.initials: Y
authors.lastname: van Hensbergen
authors.forename: Anneke
authors.initials: A
authors.lastname: Brand
authors.forename: Manon C
authors.initials: MC
authors.lastname: Slot
authors.forename: Alice
authors.initials: A
authors.lastname: de Graaf-Dijkstra
authors.forename: Arend
authors.initials: A
authors.lastname: Mulder
authors.forename: Suzanne M
authors.initials: SM
authors.lastname: Watt
authors.forename: Jaap Jan
authors.initials: JJ
authors.lastname: Zwaginga
mesh_terms: D000818:Animals; D001792:Blood Platelets / Q000378:metabolism*; D036101:Cord Blood Stem Cell Transplantation; D006085:Graft Survival / Q000187:drug effects*; D064593:Heterografts; D006801:Humans; D008297:Male; D051379:Mice; D010976:Platelet Count; D013926:Thrombopoietin / Q000494:pharmacology*; D013997:Time Factors; D018183:Transplantation Chimera / Q000097:blood*
chemical_list: D013926:Thrombopoietin